Oncology

RESCUE Study: Three-Year Interim Data Presented at ESMO 2026

Prospective real-world evidence reinforces EndoPredict’s strong prognostic performance Three-year interim results from the prospective, international RESCUE study were presented at the ESMO Congress 2026 in Madrid. The findings demonstrate that EndoPredict (EPclin) risk groups were associated with significantly different outcomes in patients with hormone receptor-positive (HR+), HER2-negative early breast cancer. The RESCUE study (Reaching for

RESCUE Study: Three-Year Interim Data Presented at ESMO 2026 Read More »

Detect prostate cancer early, better understand the personal risks, and make treatment decisions with greater confidence.

Expert Interview: “Quality of Life During Active Surveillance” Interview Partner: Prof. Dr. med. Axel Merseburger, Director of the Department of Urology, UKSH Campus Lübeck 1. What are the most common misconceptions about Active Surveillance? The biggest misconception is equating “surveillance” with “doing nothing.” Active surveillance is not the absence of treatment; it is a structured

Detect prostate cancer early, better understand the personal risks, and make treatment decisions with greater confidence. Read More »

Deciphering Lobular Breast Cancer: A Distinct Entity — Clinical Pitfalls, Biomarker Limitations, and Individualised Treatment Decisions

Blog Navigating ER+HER2− Early Breast Cancer Meritxell Bellet, MD, PhD • Mariangela Gaudio, MDVall d’Hebron University Hospital / VHIO / SOLTI, Barcelona | Eurobio Scientific Webinar, 23 April 2026 Introduction: ILC as a Distinct Biological Entity The medical and scientific understanding of invasive lobular carcinoma (ILC) has experienced a paradigm shift as the oncology community

Deciphering Lobular Breast Cancer: A Distinct Entity — Clinical Pitfalls, Biomarker Limitations, and Individualised Treatment Decisions Read More »

EndoPredict® expands laboratory accessibility through new CFX96™ Dx compatibility

EndoPredict® expands laboratory accessibility through new CFX96™ Dx compatibility June 3, 2026 Eurobio Scientific announces a significant expansion in the laboratory implementation flexibility of EndoPredict, with the addition of compatibility with the CFX96™ Dx Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.), in combination with QIAGEN RNA extraction kits. In addition to the existing and fully

EndoPredict® expands laboratory accessibility through new CFX96™ Dx compatibility Read More »

Eurobio Scientific Expands Oncology Portfolio with Genomic Assays for Urothelial Carcinoma and Cancer of Unknown or Uncertain Primary

Eurobio Scientific Expands Oncology Portfolio with Genomic Assays for Urothelial Carcinoma and Cancer of Unknown or Uncertain Primary Eurobio Scientific announces the signing of a distribution agreement with Canhelp Genomics, a company specialized in molecular diagnostics for oncology. Under this agreement, Eurobio Scientific expands distribution of the Canhelp-UCa and Canhelp-Origin tests to France, Germany, the

Eurobio Scientific Expands Oncology Portfolio with Genomic Assays for Urothelial Carcinoma and Cancer of Unknown or Uncertain Primary Read More »

Phase III EndoPredict study

ESMO Breast 2026: Long-term evidence confirms reproducibility and value of local EndoPredict testing

ESMO Breast 2026: Long-term evidence confirms reproducibility and value of local EndoPredict testing New data presented at ESMO Breast 2026 provide robust long-term evidence supporting the reproducibility of EndoPredict in routine clinical practice across decentralized laboratory settings. The results are based on an 8-year national external quality control program in France (2017–2025), in which EndoPredict

ESMO Breast 2026: Long-term evidence confirms reproducibility and value of local EndoPredict testing Read More »

PRELUDE Registry Presented at EBCC 2026

PRELUDE Registry Presented at EBCC 2026 We are pleased to share that the PRELUDE registry was presented at the European Breast Cancer Conference (EBCC) 2026 in Barcelona, Spain. Presented by Dr. Georgios Metaxas (Elena Venizelou General Hospital, Athens, Greece), the study was featured in the Precision Medicine session (Poster 333). PRELUDE (Prospective, Multicenter REgistry to

PRELUDE Registry Presented at EBCC 2026 Read More »

New Meta-Analysis Strengthens Evidence for Prolaris in Localized Prostate Cancer

New data presented at the ASCO Genitourinary Cancers Symposium provide robust evidence supporting the clinical utility of Prolaris in patients with localized prostate cancer. The findings are based on a large-scale individual participant data (IPD) meta-analysis including 7,926 patients from 14 studies (15 cohorts), representing one of the most comprehensive evaluations of a genomic test

New Meta-Analysis Strengthens Evidence for Prolaris in Localized Prostate Cancer Read More »

Phase III EndoPredict study

New German S3 Breast Cancer Guideline

New German S3 Breast Cancer Guideline Confirms Clinical Value of Multigene Tests and Emphasizes Nuanced Interpretation of Randomized Evidence Eurobio Scientific welcomes the update, which emphasizes the value of multigene assays in treatment planning, and encourages a nuanced view of randomized trial data. Currently, four multigene assays are recognized as clinically validated within the guideline:

New German S3 Breast Cancer Guideline Read More »

Phase III EndoPredict study

First Real-World Results from RESCUE Trial​

Eurobio Scientific Announces First Real-World Results from RESCUE Trial Confirming EndoPredict’s Impact in Early Luminal Breast Cancer Eurobio Scientific is proud to announce the first results from the RESCUE trial, the largest prospective, international, multicenter real-world study evaluating EndoPredict® in early luminal breast cancer. Performed by NOGGO e.V., the study recruited a total of 1,191

First Real-World Results from RESCUE Trial​ Read More »

Retour en haut